MiR-99a靶向卷曲蛋白抑制角质形成细胞增殖的分子机制

doi:10.3969/j.issn.1671-7171.2017.06.001

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】The present study is aimed to investigate the molecular mechanism of miR-99a targeting FZD5/FZD8 to inhibit the proliferation of keratinocytes in psoriasis. 【Methods】The expression levels of miR-99a, FZD5/FZD8, β-catenin and CyclinD1 in tissues and cell lines were detected by QPCR and Western Blot. The proliferation of keratinocytes was detected by MTT and BrdU assays. The target gene of miR-99a was verified by dual luciferase reporter gene assay. 【Results】The expression of miR-99a was significantly down-regulated in psoriatic lesions. Overexpressed miR-99a downregulated the expression of FZD5/FZD8, β-catenin and CyclinD1, and inhibited keratinocyte proliferation as well. On the other hand, the inhibition of miR-99a showed upregulated FZD5/FZD8, β-catenin and CyclinD1 expression, while keratinocyte proliferation got enhanced. It was found that miR-99a targeted the regulation of FZD5 and FZD8. Overexpression of FZD5/FZD8 restored the inhibitory effect of miR-99a on β-catenin and CyclinD1 proteins. The expression of miR-99a and FZD5/FZD8 was inversely correlated. 【Conclusion】 MiR-99 can target FZD5/FZD8 gene to down-regulate their expression and inhibit keratinocyte proliferation through β-catenin/CyclinD1 signaling.

Key words： MicroRNAs Keratinocytes Cell Proliferation

Received: 10 May 2017

PACS:

R329.2

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	SHEN Hui
	LIU Wen
	YAO Xiao-lei
	et al

Cite this article:

SHEN Hui,LIU Wen,YAO Xiao-lei, et al. MiR-99a Inhibits Keratinocyte Proliferation by Targeting Frizzled-5(FZD5)/FZD8 in Psoriasis[J]. JOURNAL OF CLINICAL RESEARCH, 2017, 34(6): 1041-1046.

URL:

http://www.jcr.net.cn/EN/10.3969/j.issn.1671-7171.2017.06.001 OR http://www.jcr.net.cn/EN/Y2017/V34/I6/1041

[1] Boehncke, WH. The psoriatic march: a concept of how severe psoriasis may drive cardiovascular comorbidity[J].Exp Dermatol,2011,20(4):303-307.
[2] Gladman DD, Antoni C, Mease P,et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome[J].Ann Rheum Dis,2005,2:ii14-7.
[3] Koo J.Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment[J].Dermatol Clin,1996,14(3): 485-496.
[4] Neimann AL, Shin DB, Wang X, et al. Prevalence of cardiovascular risk factors in patients with psoriasis[J].J Am Acad Dermatol,2006, 55(5): 829-835.
[5] Schon MP.Advances in psoriasis treatment[J].Lancet,2005,366(9494):1333-1335.
[6] Albanesi C, De Pita O,Girolomoni G. Resident skin cells in psoriasis: a special look at the pathogenetic functions of keratinocytes[J].Clin Dermatol,2007, 25(6):581-588.
[7] Tao J, Yang J, Wang L,et al.Expression of GLUT-1 in psoriasis and the relationship between GLUT-1 upregulation induced by hypoxia and proliferation of keratinocyte growth[J].J Dermatol Sci,2008,51(3):203-207.
[8] Ambros V, Lee RC, Lavanway A, et al. MicroRNAs and other tiny endogenous RNAs in C. Elegans[J].Curr Biol,2003,13(10):807-818.
[9] Czech MP. MicroRNAs as therapeutic targets[J].N Engl J Med,2006, 354(11): 1194-1195.
[10] Yang Z, Zeng B, Tang X,et al.MicroRNA-146a and miR-99a are potential biomarkers for disease activity and clinical efficacy assessment in psoriasis patients treated with traditional Chinese medicine[J].J Ethnopharmacol,2016,194:727-732.
[11] Clevers H.Wnt/beta-catenin signaling in development and disease[J].Cell,2006,127(3):469-480.
[12] Logan CY,Nusse R.The Wnt signaling pathway in development and disease[J].Annu Rev Cell Dev Biol,2004,20:781-810.
[13] Xiao YF, Yong X, Tang B, et al. Notch and Wnt signaling pathway in cancer: Crucial role and potential therapeutic targets (Review)[J].Int J Oncol,2016,48(2):437-449.
[14] Zhan T, Rindtorff N,Boutros M. Wnt signaling in cancer[J].Oncogene,2017,36(11):1461-1473.
[15] Corrigan PM,Dobbin E, Freeburn RW,et al. Patterns of Wnt/Fzd/LRP gene expression during embryonic hematopoiesis[J].Stem Cells Dev,2009,18(5):759-772.
[16] Chong HT, Kopecki Z, Cowin AJ.Lifting the silver flakes: the pathogenesis and management of chronic plaque psoriasis[J].Biomed Res Int,2013, 2013:168-321.
[17] Harden JL.The immunogenetics of Psoriasis: A comprehensive review[J].J Autoimmun,2015, 64:66-73.
[18] Albanesi C,Pastore S. Pathobiology of chronic inflammatory skin diseases: interplay between keratinocytes and immune cells as a target for anti-inflammatory drugs[J].Curr Drug Metab,2010, 11(3):210-227.
[19] Sonkoly E.The expanding microRNA world in psoriasis[J].Exp Dermatol,2017,26(4):375-376.
[20] Van Gele M, Bracke S, Alves de Medeiros AK,et al. Exploring the feasibility of whole blood to identify systemic miRNA biomarkers for patients with moderate to severe psoriasis[J].Eur J Dermatol,2016, 26(2):195-198.
[21] Feng C, Bai M, Yu NZ,et al. MicroRNA-181b negatively regulates the proliferation of human epidermal keratinocytes in psoriasis through targeting TLR4[J].J Cell Mol Med,2017,21(2):278-285.
[22] Hawkes JE, Nguyen GH, Fujita M, et al.MicroRNAs in Psoriasis[J].J Invest Dermatol,2016,136(2):365-371.
[23] Malbon CC.Frizzleds: new members of the superfamily of G-protein-coupled receptors[J].Front Biosci,2004,9:1048-1058.
[24] Huang HC,Klein PS.The Frizzled family: receptors for multiple signal transduction pathways[J].Genome Biol,2004, 5(7):234.
[25] Ueno K,Hirata H, Hinoda Y, et al. Frizzled homolog proteins, microRNAs and Wnt signaling in cancer[J].Int J Cancer,2013,132(8):1731-1740.
(本文编辑:师晓阳) [收稿日期] 2017-05-10

[1]	. [J]. JOURNAL OF CLINICAL RESEARCH, 2017, 34(5): 940-943.